145 related articles for article (PubMed ID: 12777961)
1. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
Yu AM; Idle JR; Herraiz T; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Jun; 13(6):307-19. PubMed ID: 12777961
[TBL] [Abstract][Full Text] [Related]
2. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
[TBL] [Abstract][Full Text] [Related]
3. Pinoline may be used as a probe for CYP2D6 activity.
Jiang XL; Shen HW; Yu AM
Drug Metab Dispos; 2009 Mar; 37(3):443-6. PubMed ID: 19095720
[TBL] [Abstract][Full Text] [Related]
4. Tryptamine: a possible endogenous substrate for CYP2D6.
Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
[TBL] [Abstract][Full Text] [Related]
5. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
Yu AM; Idle JR; Krausz KW; Küpfer A; Gonzalez FJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):315-22. PubMed ID: 12649384
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
7. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
9. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
10. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.
Yu AM; Granvil CP; Haining RL; Krausz KW; Corchero J; Küpfer A; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2003 Feb; 304(2):539-46. PubMed ID: 12538805
[TBL] [Abstract][Full Text] [Related]
11. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.
Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL
Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727
[TBL] [Abstract][Full Text] [Related]
12. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
13. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
14. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
15. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Ozdemir V; Bertilsson L; Miura J; Carpenter E; Reist C; Harper P; Widén J; Svensson JO; Albers LJ; Kennedy JL; Endrenyi L; Kalow W
Pharmacogenet Genomics; 2007 May; 17(5):339-47. PubMed ID: 17429316
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
18. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
